Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Operating Expenses (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Operating Expenses for 5 consecutive years, with $11.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 80.8% to $11.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $64.6 million, a 71.64% decrease, with the full-year FY2025 number at $98.4 million, down 56.75% from a year prior.
  • Operating Expenses was $11.3 million for Q4 2025 at Lexicon Pharmaceuticals, down from $26.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $65.4 million in Q3 2024 to a low of $11.3 million in Q4 2025.
  • A 3-year average of $42.3 million and a median of $46.4 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 48.98% in 2024, then tumbled 80.8% in 2025.
  • Lexicon Pharmaceuticals' Operating Expenses stood at $47.4 million in 2023, then increased by 24.43% to $58.9 million in 2024, then plummeted by 80.8% to $11.3 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Operating Expenses are $11.3 million (Q4 2025), $26.4 million (Q3 2025), and $26.9 million (Q1 2025).